NDAORALCAPSULE, DELAYED RELEASE
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
7/8 — Comprehensive
VUMERITY (diroximel fumarate) by Biogen is unknown. Approved for relapsing forms of multiple sclerosis, multiple sclerosis. First approved in 2019.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VUMERITY (diroximel fumarate) is an oral delayed-release capsule approved in October 2019 for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The active metabolite, monomethyl fumarate (MMF), activates the Nrf2 pathway to modulate cellular responses to oxidative stress and acts as a nicotinic acid receptor agonist. As an oral immunomodulatory agent, VUMERITY positions itself as a first-line treatment option for MS patients seeking oral convenience over injectable or infusion-based therapies.
$0.2BPart D
7.5 years to LOEMechanism of Action
unknown. MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a…
Indications (2)
Worked on VUMERITY at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.